Juliano T. Freitas

Juliano T. Freitas

Auto-generated profile, based on publicly available information

Juliano T. Freitas

Department of Biological Sciences Florida International University Miami FL USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CMCharles Marusak
Charles Marusak
VTVarsha Thakur
Varsha Thakur
YLYuan Li
Yuan Li
JFJuliano T. Freitas
Juliano T. Freitas
PZPatrick M. Zmina
Patrick M. Zmina
BBBarbara Bedogni
Barbara Bedogni
Purpose: The extracellular matrix (ECM) is an intriguing, yet understudied component of therapy resistance. Here, we investigated the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant melanoma to BRAF inhibitor (BRAFi) therapy. Experimental Design: Publicly available RNA-sequencing data and reverse phase protein array were used to determine the relevance of MT1-MMP upregulation in BRAFi-resistant melanoma in patients, patient-derived xenografts, and cell line–derived tumors. Short hairpin RNA (shRNA)-mediated knockdown of MT1-MMP, inhibition via the selective MT1-MMP/MMP2 inhibitor, ND322, or overexpression of MT1-MMP was used to assess the role of MT1-MMP in mediating resistance to BRAFi. Results: MT1-MMP was consistently upregulated in posttreatment tumor samples derived from patients upon disease progression and in melanoma xenografts and cell lines that acquired resistance to BRAFi. shRNA- or ND322-mediated inhibition of MT1-MMP synergized with BRAFi leading to resensitization of resistant cells and tumors to BRAFi. The resistant phenotype depends on the ability of cells to cleave the ECM. Resistant cells seeded in MT1-MMP uncleavable matrixes were resensitized to BRAFi similarly to MT1-MMP inhibition. This is due to the inability of cells to activate integrinβ1 (ITGB1)/FAK signaling, as restoration of ITGB1 activity is sufficient to maintain resistance to BRAFi in the context of MT1-MMP inhibition. Finally, the increase in MT1-MMP in BRAFi-resistant cells is TGFβ dependent, as inhibition of TGFβ receptors I/II dampens MT1-MMP overexpression and restores sensitivity to BRAF inhibition. Conclusions: BRAF inhibition results in a selective pressure toward higher expression of MT1-MMP. MT1-MMP is pivotal to an ECM-based signaling pathway that confers resistance to BRAFi therapy.

20 July 2021 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
JFJuliano T. Freitas
Juliano T. Freitas
JLJesus Lopez
Jesus Lopez
CLClaudia Llorian
Claudia Llorian
MBMariana Boroni
Mariana Boroni
LKLidia Kos
Lidia Kos

31 March 2023
Verified
Other
Open access
CMCharles Marusak
Charles Marusak
VTVarsha Thakur
Varsha Thakur
YLYuan Li
Yuan Li
JFJuliano T. Freitas
Juliano T. Freitas
PZPatrick M. Zmina
Patrick M. Zmina
BBBarbara Bedogni
Barbara Bedogni

31 March 2023
Verified
Other
Open access
CMCharles Marusak
Charles Marusak
VTVarsha Thakur
Varsha Thakur
YLYuan Li
Yuan Li
JFJuliano T. Freitas
Juliano T. Freitas
PZPatrick M. Zmina
Patrick M. Zmina
BBBarbara Bedogni
Barbara Bedogni

31 March 2023
Verified
Other
Open access
CMCharles Marusak
Charles Marusak
VTVarsha Thakur
Varsha Thakur
YLYuan Li
Yuan Li
JFJuliano T. Freitas
Juliano T. Freitas
PZPatrick M. Zmina
Patrick M. Zmina
BBBarbara Bedogni
Barbara Bedogni

31 March 2023
Verified
Other
Open access
CMCharles Marusak
Charles Marusak
VTVarsha Thakur
Varsha Thakur
YLYuan Li
Yuan Li
JFJuliano T. Freitas
Juliano T. Freitas
PZPatrick M. Zmina
Patrick M. Zmina
BBBarbara Bedogni
Barbara Bedogni
Pathway activation upon BRAFi resistance